PRISM MEDICO AND PHARMACY LIMITED

Subject: Outcome of the Board Meeting - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nature of Disclosure: Regulatory filing pursuant to SEBI LODR Regulations, Reg. 30, regarding outcomes of the Board of Directors meeting held on August 24, 2026.

Meeting Details:

  • Held on Tuesday, August 24, 2026.
  • Commenced at 1:00 PM and concluded at 4:00 PM.

Board Approvals and Recommendations:

1. Director's Report: Approved the Director's Report along with all necessary annexures for the Financial Year ended March 31, 2026.

2. 24th Annual General Meeting (AGM):

  • Approved the notice of the 24th AGM.
  • Date: Saturday, September 19, 2026.
  • Time: 12:30 PM.
  • Mode: Video Conferencing/Other Audio-Visual Means.

3. Register of Members Closure:

  • Fixed the closure period from September 13, 2026, to September 19, 2026 (both days inclusive).
  • Purpose: For the 24th Annual General Meeting.

4. E-Voting Cut-off Date:

  • Fixed September 12, 2026, as the cut-off date to determine shareholder eligibility to cast electronic votes at the AGM.

5. Scrutinizer Appointment:

  • Approved the appointment of Mr. Mast Ram Chechi, proprietor of M/s. M. R. Chechi and Associates, Company Secretaries, Chandigarh, as the scrutinizer to conduct the e-voting process for the 24th AGM.

6. Statutory Auditors:

  • Recommended the re-appointment of M/s. Garg Mendiratta and Associates, Chartered Accountants.
  • Remuneration was fixed (amount not disclosed).

7. Secretarial Auditors:

  • Recommended the appointment of M/s. SDK & Associates, Practicing Company Secretaries.
  • Term: For five financial years, from FY 2026-2027 to FY 2030-2031.

8. Fund Investment:

  • Recommended investing company funds as per the provisions of Section 186 of the Companies Act, 2013.

9. Variation in Preferential Issue Objects:

  • Considered and recommended a variation in the objects of the Preferential Issue and the utilisation of its proceeds.
  • This issue was originally approved by members in an Extraordinary General Meeting held on March 20, 2026.

Financial Impact: Not quantified in the disclosure.

The disclosure was signed by Davender Singh, Director (DIN: 09447213).